Hostname: page-component-84b7d79bbc-2l2gl Total loading time: 0 Render date: 2024-08-03T20:33:44.140Z Has data issue: false hasContentIssue false
  • English
  • Français

Valvular Heart Disease in Pergolide-Treated Parkinson's Disease

Published online by Cambridge University Press:  02 December 2014

James Scozzafava ,
Jennifer Takahashi ,
Wendy Johnston ,
Lakshmi Puttagunta  and
W.R. Wayne Martin
James Scozzafava
Affiliation:
Division of Neurology, University of Alberta, Edmonton, Alberta, Canada
Jennifer Takahashi
Affiliation:
Division of Neurology, University of Alberta, Edmonton, Alberta, Canada
Wendy Johnston
Affiliation:
Division of Neurology, University of Alberta, Edmonton, Alberta, Canada
Lakshmi Puttagunta
Affiliation:
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
W.R. Wayne Martin*
Affiliation:
Division of Neurology, University of Alberta, Edmonton, Alberta, Canada
*
Movement Disorders Clinic, Glenrose Rehabilitation Hospital, 10230-111 Avenue, Edmonton, Alberta, T5G 0B7, Canada
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

A 61-year-old woman with Parkinson's disease, receiving pergolide 1.75 mg four times daily, was admitted with progressive dyspnea.

Methods:

Investigations revealed mitral and aortic regurgitation. She underwent surgical mitral replacement and aortic repair, but had a postoperative course characterized by repeated bouts of congestive heart failure.

Results:

Severe tricuspid valve (TV) regurgitation developed within one month after the TV was reported on echocardiography to be relatively normal. Subsequent discontinuation of pergolide was associated with symptomatic improvement.

Conclusions:

This case illustrates the severity and rapidity with which cardiac valvular abnormalities can develop in patients receiving pergolide.

Résumé

RÉSUMÉContexte:

Une femme âgée de 61 ans, traitée avec du pergolide 1,75 mg quatre fois par jour pour une maladie de Parkinson, a été hospitalisée pour dyspnée progressive.

Méthodes:

L'évaluation de la patiente a mis en évidence une régurgitation mitrale et aortique. Elle a subi un remplacement mitral et une réfection aortique. Au cours des suites opératoires, elle a présenté des épisodes d'insuffisance cardiaque à répétition.

Résultats:

Bien que le rapport d'échographie ait fait état d'une tricuspide relativement normale un mois auparavant, on a constaté subséquemment une régurgitation tricuspidienne sévère. Les symptômes ont régressé à l'arrêt du pergolide.

Conclusions:

Cette observation illustre la sévérité et la rapidité d'installation de la valvulopathie cardiaque chez les patients sous pergolide.

Type
Case Report
Information
Canadian Journal of Neurological Sciences , Volume 33 , Issue 1 , February 2006 , pp. 111 - 113
Copyright
Copyright © The Canadian Journal of Neurological 2006

References

1. Graham, JR, Suby, HI, LeCompte, PR, Sadowsky, NL. Fibroticdisorders associated with methysergide therapy for headache. N Engl J Med. 66; 274:359–68.Google Scholar
2. Misch, KA. Development of heart valve lesions during methysergidetherapy. Br Med J. 74; 2:365–6.Google Scholar
3. Connolly, HM, Crary, JL, McGoon, MD, et al. Valvular heart diseaseassociated with fenfluramine-phentermine. N Engl J Med. 1997; 337:581–8.Google Scholar
4. Khan, MA, Herzog, CA, St. Peter, JV, et al. The prevalence of cardiacvalvular insufficiency assessed by transthoracic echo-cardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998; 339: 713–8.Google Scholar
5. Fitzgerald, LW, Burn, TC, Brown, BS, et al. Possible role of valvularserotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000:57:75–81.Google Scholar
6. Serratrice, J, Disdier, P, Habib, G, Viallet, F, Weiller, P. Fibroticvalvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002; 10:334–6.Google Scholar
7. Pritchett, A, Morrison, J, Edwards, W, et al. Valvular heart disease inpatients taking pergolide. Mayo Clin Proc. 2002; 77:1280–6.CrossRefGoogle Scholar
8. Van Camp, G, Flamez, A, Cosyns, B, et al. Heart valvular disease inpatients with Parkinson’s disease treated with high-dose pergolide. Neurology. 2003; 61:859–61.CrossRefGoogle Scholar
9. Van Camp, G, Flamez, A, Cosyns, B, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179–83.Google Scholar
10. Baseman, DG, O’Suilleabhain, PE, Reimold, SC, Laskar, SR, Baseman, JG, Dewey, RB. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004; 63:301–4.Google Scholar
11. Boess, FG, Martin, IL. Molecular biology of 5-HT receptors. Neuropharmacology. 1994; 33:275–317.Google Scholar